MURIEL C. MEYERS; STANLEY MILLER; JAMES W. LINMAN; FRANK H. BETHELL, F.A.C.P.
ACTH and cortisone have been put to trial in the treatment of a variety of hematologic disorders, to emerge as agents of therapeutic importance in thrombocytopenic purpura and acquired hemolytic anemia. In discussing these conditions it is implied that reference is made to the so-called idiopathic forms of the disease.
Thrombocytopenic purpura assumes a variety of clinical forms, varying widely in severity but having in common hemorrhagic manifestations associated with thrombocytopenia, increased capillary fragility, prolonged bleeding time and defective clot retraction. The marrow is active and essentially normal. The clinical course may be acute and fulminating, active but stationary, or
Learn more about subscription options.
Register Now for a free account.
MEYERS MC, MILLER S, LINMAN JW, BETHELL FH. THE USE OF ACTH AND CORTISONE IN IDIOPATHIC THROMBOCYTOPENIC PURPURA AND IDIOPATHIC ACQUIRED HEMOLYTIC ANEMIA(THE USE OF ACTH AND CORTISONE IN IDIOPATHIC THROMBOCYTOPENIC PURPURA AND IDIOPATHIC ACQUIRED HEMOLYTIC ANEMIA*). Ann Intern Med. 1952;37:352–361. doi: 10.7326/0003-4819-37-2-352
Download citation file:
Published: Ann Intern Med. 1952;37(2):352-361.
Coagulopathies, Hematology/Oncology, Platelet Disorders, Red Cell Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only